Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dharmais National Cancer Center Hospital
• Treatments: Anastrozole; Aromatase Inhibitors; Exemestane; Fluorouracil; Letrozole; Tamoxifen

Criteria

Inclusion Criteria:

• IIIB/C and IV stage of breast cancer

• received neoadjuvant hormonal therapy or neoadjuvant chemotherapy

• had first and second biopsy (surgery) within 6 months

Exclusion Criteria:

• had mastectomy before treatment

• pregnant

• disagree to enter the study

• had been given hormonal therapy or chemotherapy before study

• had contra-indication of SOB for pre-menopausal patients